« Back
Home /
Zelatriazin

Zelatriazin

Item no.	HY-132228-1mg
Manufacturer	MedChem Express
CASRN	1929519-13-0
Amount	1 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.88
Citations	[1]Reichard HA, et al. Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia [published online ahead of print, 2021 Jul 14]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00820.
Smiles	O=C(N[C@H](C1=CC=C(OC(F)(F)F)C=C1)C)CN2N=NC3=CC=CC=C3C2=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	TAK-041,NBI-1065846
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	GPR139
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	392.33
Product Description	Zelatriazin (TAK-041; NBI-1065846) is a potent and selective GPR139 agonist with an EC50 of 22 nM. Zelatriazin has the potential for the research of negative symptoms associated with schizophrenia[1].
Manufacturer - Research Area	Neurological Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; Neuronal Signaling
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-132228-1mg-safety-datasheet.pdf